Activation of DDX58/RIG‑I suppresses the growth of tumor cells by inhibiting STAT3/CSE signaling in colon cancer.

ABSTRACT: Some patients with colon cancer eventually develop metastasis during treatment, and the 5‑year survival rate of patients with metastatic colon cancer remains relatively low, which is most likely due to the ineffectiveness of the current standard treatment. Systemic treatment for patients with colon cancer has expanded from chemotherapy to targeted therapy and immunotherapy. Immunotherapy holds promise in the treatment of colon cancer. The present study revealed the role of innate immune receptor helicase DExD/H‑box helicase 58 (DDX58), which encodes retinoic acid‑inducible gene‑I (RIG‑I), in colon cancer. It was demonstrated that colon cancer patients with a low protein expression of DDX58/RIG‑I had a worse 5‑year survival rate of patients compared with patients with a high expression of D

SUBMITTER: Deng Y 

PROVIDER: S-EPMC9450811 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature